Findings of Research Misconduct, 74092-74093 [2014-29337]
Download as PDF
<![CDATA[
emcdonald on DSK67QTVN1PROD with NOTICES
74092
Federal Register / Vol. 79, No. 240 / Monday, December 15, 2014 / Notices
and 1C in Molecular Cancer
Therapeutics 9:2724–36, 2010. The
Respondent does not agree with ORI’s
finding of research misconduct and
asserts that there are extenuating
circumstances for her actions.
Specifically, ORI found that
Respondent:
1. included falsely labeled
immunoblots in Figures 1D and 2A as
follows:
a. Figure 1D (lower panel),
representing the total ERK levels in
extracts from cells exposed to 15 Gy of
gamma radiation for 0–120 minutes, by
using results from an unrelated
experiment for MAPK levels in extracts
from cells exposed to 2, 12, or 20 Gy of
gamma irradiation for 1, 5, 20, or 60
minutes
b. Figure 2A (KSR1 panel),
representing a control Flag-KSR1
immunoblot for extracts of cells
transfected with control (TRE), wildtype KSR (KSR–S), or dominant
negative inactive KSR (DN–KSR)
exposed to no radiation or 5 minutes
gamma irradiation, by using results form
an unrelated experiment for KSRtransfected cells (KSR–S) irradiated
with 0, 2, 5, 20, 15, 20 Gy irradiation
c. Figure 2A (ERK panel), representing
a control ERK immunoblot for extracts
of cells transfected with control (TRE),
wild-type KSR (KSR–S), or dominant
negative inactive KSR (DN–KSR)
exposed to no radiation or 5 minutes
gamma irradiation, by using results from
an unrelated experiment for KSRtransfected cells (KSR–S) irradiated
with 0, 2, 5, 10, 15, 20 Gy irradiation
2. included falsified images in Figures
1D, 2A, and Supplementary Figures 1B
and 1C by duplicating bands within the
figures as follows:
a. Figure 1D (top panel) for an
immunoblot for p-ERK in A431 cells, by
using the same bands to represent cells
treated with ionizing radiation for 5 and
10 minutes with the bands for 60 and 90
minutes
b. Figure 2A (top) for an in vitro
kinase assay for p-GST-Elk-1, by
duplicating lanes 2 and 5 to represent
the control plasmid (TRE) at 5 minutes
post radiation (lane 2) and the dominant
negative inactive KSR (DN–KSR) NT
lane (lane 5)
c. Supplementary Figure 1B (middle
panel) for an in vitro kinase assay for pGST–MEK, by using the same bands to
represent cells exposed to 5 and 20 Gy
ionizing radiation
d. Supplementary Figure 1C (top
panel) for an immunoblot for p-MEK1/
2, by using the same bands to represent
cells exposed to 2 and 20 Gy ionizing
radiation
VerDate Sep<11>2014
04:14 Dec 13, 2014
Jkt 235001
Dr. Xing has entered into a Voluntary
Settlement Agreement (Agreement) and
has voluntarily agreed:
(1) that if within three (3) years from
the effective date of the Agreement,
Respondent receives or applies for U.S.
Public Health Service (PHS) support,
Respondent agrees to have her PHSsupported research supervised for a
period of three (3) years beginning on
the date of her employment in which
she receives or applies for PHS support,
and to notify her employer(s)/
institution(s) of the terms of this
supervision; Respondent agrees that
prior to the submission of an
application for PHS support for a
research project on which the
Respondent’s participation is proposed
and prior to Respondent’s participation
in any capacity on PHS-supported
research, Respondent shall ensure that a
plan for supervision of her duties is
submitted to ORI for approval; the
supervision plan must be designed to
ensure the scientific integrity of
Respondent’s research; Respondent
agrees that she shall not participate in
any PHS-supported research until such
a supervision plan is submitted to and
approved by ORI; Respondent agrees to
maintain responsibility for compliance
with the agreed upon supervision plan;
(2) that if within three (3) years from
the effective date of this Agreement,
Respondent receives or applies for PHS
support, for a period of three (3) years
beginning on the date of her
employment in which she receives or
applies for PHS support, any institution
employing her to work on PHSsupported projects shall submit, in
conjunction with each application for
PHS funds, or report, manuscript, or
abstract involving PHS-supported
research in which Respondent is
involved, a certification to ORI that the
data provided by Respondent are based
on actual experiments or are otherwise
legitimately derived and that the data,
procedures, and methodology are
accurately reported in the application,
report, manuscript, or abstract; and
(3) to exclude herself voluntarily from
serving in any advisory capacity to PHS
including, but not limited to, service on
any PHS advisory committee, board,
and/or peer review committee, or as a
consultant for a period of three (3) years
beginning on November 13, 2014.
FOR FURTHER INFORMATION CONTACT:
Acting Director, Office of Research
Integrity, 1101 Wootton Parkway, Suite
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
750, Rockville, MD 20852, (240) 453–
8200.
Donald Wright,
Acting Director, Office of Research Integrity.
[FR Doc. 2014–29295 Filed 12–12–14; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
Office of the Secretary, HHS.
Notice.
AGENCY:
ACTION:
Notice is hereby given that
the Office of Research Integrity (ORI)
has taken final action in the following
case:
James P. Warne, Ph.D., University of
California San Francisco: Based on an
assessment conducted by the University
of California San Francisco (UCSF), the
Respondent’s admission, and additional
analysis conducted by ORI in its
oversight review, ORI found that Dr.
James P. Warne, former Senior Scientist,
Diabetes Center, UCSF School of
Medicine, engaged in research
misconduct in research supported by
National Institute of Diabetes and
Digestive and Kidney Diseases (NIDDK),
National Institutes of Health (NIH),
grants DK080427, DK007161, and
DK063720.
ORI found that Respondent engaged
in research misconduct by falsifying
data that were included in the following
two (2) publications and two (2) grant
applications:
• Cell Metabolism 14:791–803, 2011
(hereafter referred to as the ‘‘Cell
Metabolism paper’’)
• Journal of Neuroscience
33(29):11972–85, 2013 (hereafter
referred to as the ‘‘Journal of
Neuroscience paper’’)
• R01 DK080427–06A1 submitted to
NIDDK, NIH
• R01 AA022665–01A1 submitted to
the National Institute on Alcohol Abuse
and Alcoholism (NIAAA), NIH
ORI found that Respondent falsified
data and related text by altering the
experimental data to support the
experimental hypothesis. Specifically:
1. Respondent fabricated graphs
purported to represent the results of ten
(10) different ELISA experiments
measuring norephinephrin (NE) or
leptin levels in wild-type mice, in AGRP
knockout mice, or in AGRP RNAi mice
and controls that had received brain
infusions of alpha-MPT, a tyrosine
hydroxylase inhibitor or vehicle and
leptin or AGRP in the following figures:
SUMMARY:
E:\FR\FM\15DEN1.SGM
15DEN1
emcdonald on DSK67QTVN1PROD with NOTICES
Federal Register / Vol. 79, No. 240 / Monday, December 15, 2014 / Notices
• Figures 2D/E, 3G, and 7C in the Cell
Metabolism paper
• Figures 6B/C/E, Figure 8C, and Figure
9H in the Journal of Neuroscience
paper; Figures 6B/C/E of the Journal
of Neuroscience paper also were
included as Figures 5A/C/B in grant
application DK080427–06A1, and
Figure 8C of the Journal of
Neuroscience paper also was included
as Figure 8C in grant application
DK080427–06A1
• Figure 10B in grant application
DK080427–06A1
2. Respondent fabricated graphs
purported to represent the results of six
(6) different quantitative polymerase
chain reaction (Q–PCR) experiments
measuring mRNA levels in mouse liver
from wild-type or AGRP RNAi mice and
controls that had received brain
infusions of alpha-MPT, a tyrosine
hydroxylase inhibitor or vehicle and
leptin, AGRP knockout mice injected
with ethanol, or wild-type mice injected
with ethanol and caffeine in the
following figures:
• Figure 2F in the Cell Metabolism
paper
• Figures 5A, 6F, and 9A in the Journal
of Neuroscience paper; Figure 5A of
the Journal of Neuroscience paper
also was included as Figure 4A in
grant application DK080427–06A1,
and Figure 6F of the Journal of
Neuroscience paper also was included
as Figure 7A in grant application
DK080427–06A1
• Figure 3B in grant application
AA022665–06A1
Dr. Warne has entered into a Voluntary
Settlement Agreement (Agreement) and
has voluntarily agreed:
(1) to have his research supervised for
a period of three (3) years, beginning on
November 18, 2014; Respondent agrees
that prior to the submission of an
application for U.S. Public Health
Service (PHS) support for a research
project on which the Respondent’s
participation is proposed and prior to
Respondent’s participation in any
capacity on PHS-supported research,
Respondent shall ensure that a plan for
supervision of his duties is submitted to
ORI for approval; the supervision plan
must be designed to ensure the
scientific integrity of Respondent’s
research contribution; Respondent
agrees that he shall not participate in
any PHS-supported research until such
a supervision plan is submitted to and
approved by ORI; Respondent agrees to
maintain responsibility for compliance
with the agreed upon supervision plan;
(2) that for a period of three (3) years,
beginning on November 18, 2014, any
institution employing him shall submit,
VerDate Sep<11>2014
02:54 Dec 13, 2014
Jkt 235001
in conjunction with each application for
PHS funds, or report, manuscript, or
abstract involving PHS-supported
research in which Respondent is
involved, a certification to ORI that the
data provided by Respondent are based
on actual experiments or are otherwise
legitimately derived and that the data,
procedures, and methodology are
accurately reported in the application,
report, manuscript, or abstract;
(3) to exclude himself voluntarily
from serving in any advisory capacity to
PHS including, but not limited to,
service on any PHS advisory committee,
board, and/or peer review committee, or
as a consultant for a period of three (3)
years, beginning on November 18, 2014;
and
(4) that as a condition of the
Agreement, the senior authors will
request retraction or correction of the
following papers:
• Cell Metabolism 14:791–803, 2011
• Journal of Neuroscience
33(29):11972–85, 2013
FOR FURTHER INFORMATION CONTACT:
Acting Director, Office of Research
Integrity, 1101 Wootton Parkway, Suite
750, Rockville, MD 20852, (240) 453–
8200.
Donald Wright,
Acting Director, Office of Research Integrity.
[FR Doc. 2014–29337 Filed 12–12–14; 8:45 am]
BILLING CODE 4150–31–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Toxic Substances and
Disease Registry
[Docket No. ATSDR–2014–0001]
Availability of Draft Toxicological
Profiles
Agency for Toxic Substances
and Disease Registry (ATSDR),
Department of Health and Human
Services (DHHS).
ACTION: Notice of availability, and
request for comments.
AGENCY:
This notice announces the
availability of Set 26 Toxicological
Profiles for review and comment.
Comments can include additional
information or reports on studies about
the health effects of Set 26 substances.
Although ATSDR considered key
studies for each of these substances
during the profile development process,
this Federal Register notice solicits any
relevant, additional studies, particularly
unpublished data. ATSDR will evaluate
the quality and relevance of such data
or studies for possible inclusion into the
SUMMARY:
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
74093
profile. ATSDR remains committed to
providing a public comment period for
this document as a means to best serve
public health and our clients. The Set
26 Toxicological Profiles are available
online at https://www.atsdr.cdc.gov/
toxprofiles/index.asp and https://
www.regulations.gov/#!home, docket
ATSDR–2014–0001.
The Comprehensive Environmental
Response, Compensation, and Liability
Act of 1980 (CERCLA), as amended by
the Superfund Amendments and
Reauthorization Act of 1986 (SARA),
§ 104(i)(3),[42 U.S.C. 9604(i)(3)], directs
the ATSDR administrator to prepare
Toxicological Profiles of priority
hazardous substances and, as necessary,
to revise and publish each updated
toxicological profile.
DATES: To be considered, comments on
the draft Toxicological Profiles must be
received not later than March 16, 2015.
Comments received after close of the
public comment period will be
considered solely at the discretion of
ATSDR, based upon what is deemed to
be in the best interest of the general
public.
ADDRESSES: You may submit comments,
identified by docket number ATSDR–
2014–0001, by any of the following
methods:
• Federal eRulemaking Portal: https://
www.regulations.gov/#!home. Follow
the instructions for submitting
comments.
• Mail: Division of Toxicology and
Human Health Sciences, 1600 Clifton
Rd., NE., MS F57, Atlanta, Ga., 30333.
Instructions: All submissions received
must include the agency name and
docket number for this notice. All
relevant comments will be posted
without change. Because all public
comments regarding ATSDR
Toxicological Profiles are available for
public inspection, no confidential
business information or other
confidential information should be
submitted in response to this notice.
FOR FURTHER INFORMATION CONTACT: Ms.
Delores Grant, Division of Toxicology
and Human Health Sciences, 1600
Clifton Rd., NE., MS F–57, Atlanta, Ga.,
30333. Phone: 770–488–3351.
SUPPLEMENTARY INFORMATION: The
Comprehensive Environmental
Response, Compensation, and Liability
Act, as amended (CERCLA or
Superfund) (42 U.S.C. 9601 et seq.)
establishes certain responsibilities for
ATSDR and the U.S. Environmental
Protection Agency (U.S. EPA) with
regard to hazardous substances most
commonly found at facilities on the
CERCLA National Priorities List (NPL).
As part of these responsibilities, the
E:\FR\FM\15DEN1.SGM
15DEN1
]]>Agencies
[Federal Register Volume 79, Number 240 (Monday, December 15, 2014)]
[Notices]
[Pages 74092-74093]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-29337]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
AGENCY: Office of the Secretary, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Notice is hereby given that the Office of Research Integrity
(ORI) has taken final action in the following case:
James P. Warne, Ph.D., University of California San Francisco:
Based on an assessment conducted by the University of California San
Francisco (UCSF), the Respondent's admission, and additional analysis
conducted by ORI in its oversight review, ORI found that Dr. James P.
Warne, former Senior Scientist, Diabetes Center, UCSF School of
Medicine, engaged in research misconduct in research supported by
National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK), National Institutes of Health (NIH), grants DK080427,
DK007161, and DK063720.
ORI found that Respondent engaged in research misconduct by
falsifying data that were included in the following two (2)
publications and two (2) grant applications:
Cell Metabolism 14:791-803, 2011 (hereafter referred to as
the ``Cell Metabolism paper'')
Journal of Neuroscience 33(29):11972-85, 2013 (hereafter
referred to as the ``Journal of Neuroscience paper'')
R01 DK080427-06A1 submitted to NIDDK, NIH
R01 AA022665-01A1 submitted to the National Institute on
Alcohol Abuse and Alcoholism (NIAAA), NIH
ORI found that Respondent falsified data and related text by altering
the experimental data to support the experimental hypothesis.
Specifically:
1. Respondent fabricated graphs purported to represent the results
of ten (10) different ELISA experiments measuring norephinephrin (NE)
or leptin levels in wild-type mice, in AGRP knockout mice, or in AGRP
RNAi mice and controls that had received brain infusions of alpha-MPT,
a tyrosine hydroxylase inhibitor or vehicle and leptin or AGRP in the
following figures:
[[Page 74093]]
Figures 2D/E, 3G, and 7C in the Cell Metabolism paper
Figures 6B/C/E, Figure 8C, and Figure 9H in the Journal of
Neuroscience paper; Figures 6B/C/E of the Journal of Neuroscience paper
also were included as Figures 5A/C/B in grant application DK080427-
06A1, and Figure 8C of the Journal of Neuroscience paper also was
included as Figure 8C in grant application DK080427-06A1
Figure 10B in grant application DK080427-06A1
2. Respondent fabricated graphs purported to represent the results
of six (6) different quantitative polymerase chain reaction (Q-PCR)
experiments measuring mRNA levels in mouse liver from wild-type or AGRP
RNAi mice and controls that had received brain infusions of alpha-MPT,
a tyrosine hydroxylase inhibitor or vehicle and leptin, AGRP knockout
mice injected with ethanol, or wild-type mice injected with ethanol and
caffeine in the following figures:
Figure 2F in the Cell Metabolism paper
Figures 5A, 6F, and 9A in the Journal of Neuroscience paper;
Figure 5A of the Journal of Neuroscience paper also was included as
Figure 4A in grant application DK080427-06A1, and Figure 6F of the
Journal of Neuroscience paper also was included as Figure 7A in grant
application DK080427-06A1
Figure 3B in grant application AA022665-06A1
Dr. Warne has entered into a Voluntary Settlement Agreement (Agreement)
and has voluntarily agreed:
(1) to have his research supervised for a period of three (3)
years, beginning on November 18, 2014; Respondent agrees that prior to
the submission of an application for U.S. Public Health Service (PHS)
support for a research project on which the Respondent's participation
is proposed and prior to Respondent's participation in any capacity on
PHS-supported research, Respondent shall ensure that a plan for
supervision of his duties is submitted to ORI for approval; the
supervision plan must be designed to ensure the scientific integrity of
Respondent's research contribution; Respondent agrees that he shall not
participate in any PHS-supported research until such a supervision plan
is submitted to and approved by ORI; Respondent agrees to maintain
responsibility for compliance with the agreed upon supervision plan;
(2) that for a period of three (3) years, beginning on November 18,
2014, any institution employing him shall submit, in conjunction with
each application for PHS funds, or report, manuscript, or abstract
involving PHS-supported research in which Respondent is involved, a
certification to ORI that the data provided by Respondent are based on
actual experiments or are otherwise legitimately derived and that the
data, procedures, and methodology are accurately reported in the
application, report, manuscript, or abstract;
(3) to exclude himself voluntarily from serving in any advisory
capacity to PHS including, but not limited to, service on any PHS
advisory committee, board, and/or peer review committee, or as a
consultant for a period of three (3) years, beginning on November 18,
2014; and
(4) that as a condition of the Agreement, the senior authors will
request retraction or correction of the following papers:
Cell Metabolism 14:791-803, 2011
Journal of Neuroscience 33(29):11972-85, 2013
FOR FURTHER INFORMATION CONTACT: Acting Director, Office of Research
Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240)
453-8200.
Donald Wright,
Acting Director, Office of Research Integrity.
[FR Doc. 2014-29337 Filed 12-12-14; 8:45 am]
BILLING CODE 4150-31-P
